Ruixing Zhang

机构：Beihang University · ORCID：0000-0001-7341-0631

发表论文 87 篇 · 总被引 1154 次 · h-index 17

代表论文

• Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial (2024 · BMJ · 被引 265)
• First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial (2025 · Nature Medicine · 被引 88)
• First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer (2025 · JAMA · 被引 70)
• Mechanism of Exogenous Silicon in Enhancing Cold Stress Tolerance in Solanum lycopersicum L. Seedlings: Insights from Resistance and Quality Indicators (2024 · Horticulturae · 被引 8)
• Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial (2024 · Journal of Hematology & Oncology · 被引 8)
• The RNA-Binding Protein BoRHON1 Positively Regulates the Accumulation of Aliphatic Glucosinolates in Cabbage (2024 · International Journal of Molecular Sciences · 被引 5)